Cover Image
市場調查報告書

瞬態電壓感受器陽離子通道亞族V/子類1:開發中產品分析

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364860
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
瞬態電壓感受器陽離子通道亞族V/子類1:開發中產品分析 Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 103 Pages
簡介

本報告提供以瞬態電壓感受器陽離子通道亞族V子類1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

瞬態電壓感受器陽離子通道亞族V子類1:概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Amorepacific Corporation
  • AnaBios Corporation
  • BCN Peptides, S.A.
  • Centrexion Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • DoNatur GmbH
  • Flex Pharma, Inc.
  • Grunenthal GmbH
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Neurim Pharmaceuticals Ltd
  • PharmEste
  • Pila Pharma AB
  • Sylentis S.A.U.
  • Toray Industries

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1005TDB

Summary:

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 32 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 5, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Ophthalmology, Dermatology, Oncology, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Infectious Disease which include indications Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuropathic Pain, Pain, Postherpetic Neuralgia, Chronic Pain, Osteoarthritis Pain, Abdominal Pain, Diabetic Peripheral Neuropathy, Keratoconjunctivitis sicca (Dry Eye), Pruritus, Acute Pain, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Charcot-Marie-Tooth Disease, Chronic Cough, Cluster Headache Syndrome, Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Fungal Infections, Hypertension, Inflammation, Insomnia, Memory Impairment, Morton Metatarsalgia, Motor Neuron Diseases, Multiple Sclerosis, Neuro Muscular Disorders, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Prostate Cancer, Radiculopathy, Rosacea, Seborrhea, Squamous Cell Carcinoma and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
    • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Amorepacific Corp
    • AnaBios Corp
    • BCN Peptides SA
    • Daewoong Pharmaceutical Co Ltd
    • DoNatur GmbH
    • Flex Pharma Inc
    • Grunenthal GmbH
    • Kyowa Hakko Kirin Co Ltd
    • Medifron DBT Co Ltd
    • Neurim Pharmaceuticals Ltd
    • Pila Pharma AB
    • Sylentis SAU
    • Toray Industries Inc
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
    • AMG-986 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1119 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • capsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • capsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMX-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DD-04107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-05195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-787 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-788 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-798 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-685 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDR-16523 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDR-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-6860 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NeuP-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QX-314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resiniferatoxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zucapsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
      • Jul 25, 2017: FDA Grants Fast Track Designation to Flex Pharma's FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
      • Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting
      • Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
      • Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain
      • Jun 07, 2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology
      • Jun 02, 2017: Flex Pharmas Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium
      • May 30, 2017: Sylentis initiates a Phase III study for the treatment of dry eye syndrome
      • May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress
      • May 10, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting
      • May 09, 2017: PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017
      • Apr 26, 2017: FDA Clears Flex Pharmas FLX-787 to Commence US Phase 2 Trial in ALS Under IND
      • Apr 19, 2017: Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting
      • Apr 05, 2017: Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
      • Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by Amorepacific Corp, H2 2017
  • Pipeline by AnaBios Corp, H2 2017
  • Pipeline by BCN Peptides SA, H2 2017
  • Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Pipeline by DoNatur GmbH, H2 2017
  • Pipeline by Flex Pharma Inc, H2 2017
  • Pipeline by Grunenthal GmbH, H2 2017
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Pipeline by Medifron DBT Co Ltd, H2 2017
  • Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
  • Pipeline by Pila Pharma AB, H2 2017
  • Pipeline by Sylentis SAU, H2 2017
  • Pipeline by Toray Industries Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Dormant Products, H2 2017 (Contd..4), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top